



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

December 2023





© 2024 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to people living with HIV throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

December 2023

N = 7614



Health Authority	Male	Female	All
FRASER	1539	477	2016
INTERIOR	476	115	591
NORTHERN	161	79	240
VANCOUVER COASTAL	3298	445	3743
VANCOUVER ISLAND	833	167	1000
	6307	1283	7590
		Unknown/not stated:	24
		Total:	7614

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (December 2018 - December 2023)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (December 2018 - December 2023)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (December 2018 - December 2023)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (December 2018 - December 2023)






1.6 Percent Distribution of Active Participants by CD4 Count
(December 2018 - December 2023)






1.7 Percent Distribution of Inactive Participants by CD4 Count
(December 2018 - December 2023)






1.8 Active and Inactive Participants (December 2018 - December 2023)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (December 2018 - December 2023)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (December 2018 - December 2023)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(December 2018 - December 2023)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (December 2018 - December 2023)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(December 2018 - December 2023)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (December 2018 - December 2023)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(December 2018 - December 2023)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (December 2018 - December 2023)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(December 2018 - December 2023)






1.18 Baseline CD4 for Antiretroviral First Starts
(December 2018 - December 2023)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (December 2018 - December 2023)






1.20 Cumulative Resistance Testing Results by Resistance Category (December 2018 - December 2023)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (December 2018 - December 2023)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	32	4	0	4	1	900	4	<40	4
1988	33	4	0	4	1	420	4	<40	4
1989	31	48	1	49	18	480	44	<40	3
1990	29	51	1	52	28	550	50	<40	3
1991	30	34	3	37	16	535	36	<40	3
1992	29	48	5	53	21	600	51	<40	3
1993	28	109	15	124	65	590	118	<40	3
1994	27	65	12	77	41	600	74	<40	3
1995	27	119	19	138	69	560	125	<40	3
1996	25	290	45	335	155	599	298	<40	3
1997	23	254	27	281	147	570	255	<40	3
1998	22	175	37	212	114	580	184	<40	3
1999	22	144	37	181	106	555	165	<40	3
2000	22	111	26	137	79	620	121	<40	3
2001	22	106	26	132	67	590	117	<40	3
2002	21	111	22	133	72	580	120	<40	3
2003	20	129	26	155	86	625	134	<40	3
2004	19	137	35	172	97	630	153	<40	3
2005	18	167	38	205	125	680	184	<40	3
2006	17	162	40	202	103	680	171	<40	3
2007	16	221	40	261	153	680	242	<40	3
2008	15	260	57	317	195	650	280	<40	3
2009	14	287	65	352	195	650	308	<40	3
2010	13	244	65	309	178	700	278	<40	3
2011	12	310	66	376	212	715	326	<40	3
2012	11	258	62	320	181	710	291	<40	3
2013	10	241	64	305	167	660	266	<40	3
2014	9	256	43	299	157	730	262	<40	3
2015	8	253	43	296	156	650	260	<40	3
2016	7	236	47	283	159	680	242	<40	3
2017	6	194	31	225	131	700	195	<40	3
2018	5	170	45	215	126	760	190	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	4	207	41	248	158	670	220	<40	3
2020	4	163	54	217	138	760	184	<40	3
2021	3	180	34	214	126	600	196	<40	3
2022	1	255	44	299	192	695	270	<40	3
2023	1	299	71	370	299	540	362	<40	3
Total:		6302	1287	7589					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	7465	756	1878	<40	1317	650
FEB-2022	7386	774	1803	<40	1263	620
MAR-2022	7458	766	1904	<40	1251	620
APR-2022	7420	778	1755	<40	1153	620
MAY-2022	7477	763	1998	<40	1306	620
JUN-2022	7482	759	1839	<40	1201	630
JUL-2022	7495	754	1761	<40	1141	645
AUG-2022	7492	758	1990	<40	1227	620
SEP-2022	7442	772	1787	<40	1092	636
OCT-2022	7468	778	1849	<40	1164	640
NOV-2022	7501	783	1898	<40	1202	630
DEC-2022	7543	787	1607	<40	1006	635
JAN-2023	7581	793	2051	<40	1320	650
FEB-2023	7521	807	1727	<40	1019	630
MAR-2023	7548	803	1974	<40	1214	640
APR-2023	7553	796	1761	<40	1083	630
MAY-2023	7592	786	1933	<40	1234	650
JUN-2023	7599	787	1841	<40	1095	640
JUL-2023	7577	806	1747	<40	1052	620
AUG-2023	7599	806	1814	<40	1036	630
SEP-2023	7610	797	1775	<40	1060	650
OCT-2023	7612	803	1888	<40	1142	620
NOV-2023	7619	795	1855	<40	1081	650
DEC-2023	7614	797	1551	<40	895	650

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	786	273	55	<40	45	580
FEB-2022	856	232	73	<40	56	635
MAR-2022	800	285	94	<40	73	480
APR-2022	834	278	70	<40	53	550
MAY-2022	758	317	60	<40	43	490
JUN-2022	761	291	61	<40	43	400
JUL-2022	764	283	61	<50	36	447
AUG-2022	787	261	59	78	49	560
SEP-2022	844	209	71	<40	53	460
OCT-2022	822	210	83	<40	62	495
NOV-2022	809	205	80	50	60	505
DEC-2022	774	230	57	<40	45	560
JAN-2023	734	276	63	<40	45	550
FEB-2023	787	230	66	<40	53	550
MAR-2023	756	242	78	<40	56	512
APR-2023	762	218	66	<40	47	560
MAY-2023	728	240	65	<40	48	430
JUN-2023	711	204	57	<40	39	460
JUL-2023	742	186	68	<40	50	565
AUG-2023	742	190	63	<40	40	595
SEP-2023	729	209	55	<40	41	540
OCT-2023	737	214	59	<40	44	625
NOV-2023	740	208	64	<40	45	500
DEC-2023	746	201	46	<40	34	472

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2022	7432	786	19	7	161	144	2	14485
FEB-2022	7371	856	8	9	151	211	-61	14510
MAR-2022	7432	800	16	9	232	160	61	14539
APR-2022	7397	834	11	1	156	178	-35	14559
MAY-2022	7450	758	13	13	205	146	53	14583
JUN-2022	7457	761	11	15	178	170	7	14620
JUL-2022	7469	764	10	13	188	176	12	14659
AUG-2022	7468	787	15	17	169	172	-1	14697
SEP-2022	7423	845	13	15	146	192	-46	14725
OCT-2022	7443	822	14	16	195	171	20	14760
NOV-2022	7479	809	9	17	210	177	37	14799
DEC-2022	7510	774	19	8	213	167	31	14826
JAN-2023	7550	734	20	10	193	143	40	14861
FEB-2023	7505	787	10	11	158	204	-45	14885
MAR-2023	7532	756	15	21	197	176	27	14919
APR-2023	7531	762	13	11	176	169	-1	14948
MAY-2023	7575	728	7	15	205	165	44	14992
JUN-2023	7578	711	14	17	168	165	3	15027
JUL-2023	7556	742	11	11	164	181	-22	15058
AUG-2023	7578	742	11	13	217	193	22	15103
SEP-2023	7581	729	14	5	180	163	3	15124
OCT-2023	7582	737	18	10	170	159	1	15154
NOV-2023	7586	740	17	9	185	170	4	15190
DEC-2023	7589	746	13	14	169	166	3	15224

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2022	499	6468	455	43	7465	6.68%	86.64%	6.10%	0.58%	100.00%
FEB-2022	525	6371	445	45	7386	7.11%	86.26%	6.02%	0.61%	100.00%
MAR-2022	550	6408	455	45	7458	7.37%	85.92%	6.10%	0.60%	100.00%
APR-2022	567	6357	450	46	7420	7.64%	85.67%	6.06%	0.62%	100.00%
MAY-2022	597	6381	452	47	7477	7.98%	85.34%	6.05%	0.63%	100.00%
JUN-2022	614	6376	450	42	7482	8.21%	85.22%	6.01%	0.56%	100.00%
JUL-2022	635	6371	445	45	7496	8.47%	84.99%	5.94%	0.60%	100.00%
AUG-2022	644	6364	442	43	7493	8.59%	84.93%	5.90%	0.57%	100.00%
SEP-2022	663	6295	439	45	7442	8.91%	84.59%	5.90%	0.60%	100.00%
OCT-2022	679	6308	439	41	7467	9.09%	84.48%	5.88%	0.55%	100.00%
NOV-2022	696	6317	447	41	7501	9.28%	84.22%	5.96%	0.55%	100.00%
DEC-2022	709	6343	450	41	7543	9.40%	84.09%	5.97%	0.54%	100.00%
JAN-2023	722	6371	445	44	7582	9.52%	84.03%	5.87%	0.58%	100.00%
FEB-2023	735	6318	429	39	7521	9.77%	84.00%	5.70%	0.52%	100.00%
MAR-2023	750	6312	445	41	7548	9.94%	83.62%	5.90%	0.54%	100.00%
APR-2023	766	6307	440	41	7554	10.14%	83.49%	5.82%	0.54%	100.00%
MAY-2023	803	6314	435	41	7593	10.58%	83.16%	5.73%	0.54%	100.00%
JUN-2023	821	6299	438	41	7599	10.80%	82.89%	5.76%	0.54%	100.00%
JUL-2023	844	6253	440	40	7577	11.14%	82.53%	5.81%	0.53%	100.00%
AUG-2023	867	6239	448	46	7600	11.41%	82.09%	5.89%	0.61%	100.00%
SEP-2023	882	6250	433	46	7611	11.59%	82.12%	5.69%	0.60%	100.00%
OCT-2023	900	6238	433	41	7612	11.82%	81.95%	5.69%	0.54%	100.00%
NOV-2023	920	6217	441	41	7619	12.08%	81.60%	5.79%	0.54%	100.00%
DEC-2023	939	6200	435	40	7614	12.33%	81.43%	5.71%	0.53%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	3 20%	3064 42%	3 20%	2480 34%	0 0%	19 0%	12 80%	2922 40%	0 0%	1473 20%	12 80%	4262 58%
FEB-2022	6 24%	3019 42%	3 12%	2410 33%	2 8%	19 0%	15 60%	2939 41%	4 16%	1395 19%	19 76%	4225 58%
MAR-2022	3 10%	3034 41%	2 7%	2406 33%	0 0%	19 0%	24 83%	3029 41%	2 7%	1350 18%	26 90%	4272 58%
APR-2022	4 20%	3019 41%	3 15%	2366 33%	0 0%	19 0%	14 70%	3052 42%	2 10%	1313 18%	16 80%	4250 58%
MAY-2022	4 17%	3026 41%	3 13%	2354 32%	0 0%	18 0%	17 74%	3145 43%	2 9%	1282 17%	19 83%	4309 59%
JUN-2022	5 14%	3015 41%	0 0%	2309 31%	0 0%	19 0%	29 81%	3199 44%	4 11%	1237 17%	31 86%	4320 59%
JUL-2022	4 10%	3007 41%	3 8%	2285 31%	0 0%	19 0%	27 69%	3229 44%	9 23%	1218 17%	35 90%	4343 59%
AUG-2022	5 14%	2991 41%	4 11%	2261 31%	0 0%	18 0%	29 78%	3271 45%	3 8%	1178 16%	32 86%	4354 59%
SEP-2022	4 14%	2952 40%	3 11%	2195 30%	0 0%	17 0%	19 68%	3284 45%	5 18%	1173 16%	24 86%	4352 60%
OCT-2022	6 17%	2949 40%	4 11%	2172 30%	0 0%	16 0%	29 83%	3350 46%	0 0%	1143 16%	29 83%	4388 60%
NOV-2022	7 18%	2947 40%	5 13%	2157 29%	0 0%	15 0%	26 68%	3387 46%	6 16%	1136 15%	31 82%	4417 60%
DEC-2022	4 15%	2950 40%	3 11%	2147 29%	1 4%	16 0%	18 67%	3446 47%	5 19%	1109 15%	23 85%	4445 60%
JAN-2023	6 17%	2971 40%	1 3%	2147 29%	1 3%	16 0%	23 66%	3491 47%	8 23%	1095 15%	29 83%	4465 60%
FEB-2023	3 13%	2944 40%	1 4%	2097 28%	0 0%	17 0%	18 75%	3502 47%	3 13%	1065 14%	21 88%	4446 60%
MAR-2023	2 6%	2936 40%	2 6%	2071 28%	0 0%	15 0%	27 79%	3551 48%	5 15%	1051 14%	32 94%	4476 60%
APR-2023	3 10%	2948 40%	1 3%	2067 28%	0 0%	15 0%	24 83%	3550 48%	3 10%	1030 14%	26 90%	4469 60%
MAY-2023	10 24%	2940 39%	4 10%	2043 27%	1 2%	16 0%	30 71%	3598 48%	3 7%	1040 14%	32 76%	4513 61%
JUN-2023	4 12%	2934 39%	1 3%	2008 27%	0 0%	14 0%	26 76%	3655 49%	4 12%	1002 13%	30 88%	4533 61%
JUL-2023	5 16%	2917 39%	1 3%	1966 26%	0 0%	14 0%	25 81%	3678 49%	2 6%	985 13%	26 84%	4530 61%
AUG-2023	4 9%	2909 39%	1 2%	1935 26%	0 0%	14 0%	34 76%	3716 50%	9 20%	969 13%	41 91%	4560 61%
SEP-2023	2 10%	2903 39%	1 5%	1911 26%	0 0%	13 0%	16 76%	3746 50%	3 14%	954 13%	19 90%	4578 61%
OCT-2023	2 7%	2905 39%	1 3%	1895 25%	0 0%	14 0%	22 73%	3765 50%	6 20%	937 13%	28 93%	4573 61%
NOV-2023	1 3%	2893 39%	0 0%	1867 25%	0 0%	15 0%	27 77%	3787 51%	7 20%	920 12%	34 97%	4590 61%
DEC-2023	6 18%	2877 38%	4 12%	1833 25%	0 0%	13 0%	26 76%	3826 51%	3 9%	898 12%	28 82%	4603 62%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	1 0%	0 0%	476 29%	0 0%	1132 68%	0 0%	60 4%	0 0%	1 0%	0 0%	1 0%
FEB-2022	0 0%	1 0%	1 33%	447 28%	1 33%	1110 69%	1 33%	60 4%	0 0%	1 0%	0 0%	1 0%
MAR-2022	0 0%	1 0%	0 0%	430 27%	2 100%	1113 70%	0 0%	57 4%	0 0%	1 0%	0 0%	1 0%
APR-2022	0 0%	1 0%	0 0%	424 27%	0 0%	1085 69%	0 0%	56 4%	0 0%	1 0%	0 0%	1 0%
MAY-2022	0 0%	1 0%	1 33%	417 27%	2 67%	1080 70%	0 0%	53 3%	0 0%	1 0%	0 0%	1 0%
JUN-2022	0 0%	1 0%	0 0%	407 27%	1 100%	1056 70%	0 0%	52 3%	0 0%	1 0%	0 0%	1 0%
JUL-2022	0 0%	1 0%	0 0%	405 27%	1 100%	1039 70%	0 0%	50 3%	0 0%	1 0%	0 0%	1 0%
AUG-2022	0 0%	1 0%	0 0%	385 26%	1 100%	1028 71%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
SEP-2022	0 0%	0 0%	0 0%	367 26%	2 100%	1010 71%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
OCT-2022	0 0%	0 0%	0 0%	354 25%	0 0%	1002 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
NOV-2022	0 0%	0 0%	0 0%	352 25%	6 100%	995 72%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
DEC-2022	0 0%	0 0%	0 0%	342 25%	1 100%	1008 72%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
JAN-2023	0 0%	0 0%	0 0%	339 25%	1 100%	993 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
FEB-2023	0 0%	0 0%	0 0%	321 24%	0 0%	953 73%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
MAR-2023	0 0%	0 0%	0 0%	317 24%	1 100%	952 73%	0 0%	42 3%	0 0%	1 0%	0 0%	1 0%
APR-2023	0 0%	0 0%	0 0%	305 23%	1 100%	957 74%	0 0%	41 3%	0 0%	1 0%	0 0%	1 0%
MAY-2023	0 0%	0 0%	0 0%	303 23%	2 100%	951 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUN-2023	0 0%	0 0%	0 0%	294 23%	0 0%	936 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUL-2023	0 0%	0 0%	0 0%	283 23%	3 100%	927 74%	0 0%	38 3%	0 0%	1 0%	0 0%	1 0%
AUG-2023	0 0%	0 0%	0 0%	276 23%	3 100%	914 75%	0 0%	36 3%	0 0%	0 0%	0 0%	0 0%
SEP-2023	0 0%	0 0%	1 100%	272 22%	0 0%	909 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
OCT-2023	0 0%	0 0%	0 0%	273 23%	1 100%	893 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
NOV-2023	0 0%	0 0%	1 33%	260 22%	2 67%	890 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
DEC-2023	0 0%	0 0%	0 0%	248 21%	1 100%	878 76%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	103 9%	0 0%	328 30%	0 0%	130 12%	0 0%	317 29%	0 0%	235 21%
FEB-2022	0 0%	106 10%	0 0%	317 29%	0 0%	127 12%	0 0%	306 28%	1 100%	228 21%
MAR-2022	0 0%	113 11%	1 100%	303 28%	0 0%	132 12%	0 0%	301 28%	0 0%	222 21%
APR-2022	1 50%	124 12%	1 50%	301 28%	0 0%	130 12%	0 0%	297 28%	0 0%	223 21%
MAY-2022	0 0%	136 13%	0 0%	287 27%	0 0%	128 12%	0 0%	290 27%	1 100%	220 21%
JUN-2022	1 33%	149 14%	1 33%	284 27%	0 0%	122 12%	0 0%	285 27%	1 33%	211 20%
JUL-2022	0 0%	155 15%	1 33%	280 27%	0 0%	117 11%	0 0%	280 27%	2 67%	207 20%
AUG-2022	0 0%	157 15%	1 33%	275 27%	0 0%	119 12%	0 0%	274 27%	2 67%	204 20%
SEP-2022	0 0%	167 16%	3 100%	271 27%	0 0%	110 11%	0 0%	273 27%	0 0%	200 20%
OCT-2022	0 0%	173 17%	0 0%	261 26%	0 0%	105 10%	0 0%	269 27%	0 0%	196 20%
NOV-2022	1 33%	182 18%	2 67%	261 26%	0 0%	108 11%	0 0%	269 27%	0 0%	197 19%
DEC-2022	0 0%	185 18%	1 25%	254 25%	0 0%	107 11%	1 25%	262 26%	2 50%	195 19%
JAN-2023	3 43%	192 19%	4 57%	247 25%	0 0%	107 11%	0 0%	255 26%	0 0%	191 19%
FEB-2023	0 0%	202 20%	0 0%	250 25%	0 0%	98 10%	0 0%	249 25%	0 0%	190 19%
MAR-2023	0 0%	209 21%	0 0%	242 25%	0 0%	101 10%	0 0%	246 25%	0 0%	186 19%
APR-2023	1 50%	215 22%	1 50%	232 24%	0 0%	96 10%	0 0%	245 25%	0 0%	187 19%
MAY-2023	1 33%	223 23%	0 0%	232 24%	0 0%	98 10%	0 0%	239 24%	2 67%	187 19%
JUN-2023	0 0%	224 23%	3 75%	228 24%	0 0%	96 10%	0 0%	230 24%	1 25%	180 19%
JUL-2023	0 0%	235 25%	1 100%	222 23%	0 0%	94 10%	0 0%	225 24%	0 0%	178 19%
AUG-2023	0 0%	238 25%	2 100%	222 23%	0 0%	91 10%	0 0%	223 23%	0 0%	182 19%
SEP-2023	0 0%	236 25%	0 0%	218 23%	0 0%	88 9%	1 100%	220 23%	0 0%	177 19%
OCT-2023	0 0%	239 26%	2 100%	217 23%	0 0%	89 10%	0 0%	220 24%	0 0%	173 19%
NOV-2023	0 0%	243 26%	0 0%	210 23%	1 50%	88 9%	0 0%	219 24%	1 50%	173 19%
DEC-2023	1 50%	251 27%	0 0%	206 22%	0 0%	87 9%	0 0%	213 23%	1 50%	176 19%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		cabotegravir		dolutegravir		elvitegravir		fostemsavir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	11 73%	2421 43%	0 0%	0 0%	2 13%	2468 44%	1 7%	347 6%	0 0%	1 0%	0 0%	24 0%	1 7%	374 7%
FEB-2022	15 71%	2443 44%	0 0%	0 0%	6 29%	2437 44%	0 0%	331 6%	0 0%	1 0%	0 0%	21 0%	0 0%	369 7%
MAR-2022	23 85%	2536 45%	0 0%	0 0%	3 11%	2460 43%	1 4%	324 6%	0 0%	1 0%	0 0%	21 0%	0 0%	370 7%
APR-2022	14 74%	2574 45%	0 0%	0 0%	5 26%	2436 43%	0 0%	312 5%	0 0%	1 0%	0 0%	20 0%	0 0%	366 6%
MAY-2022	17 77%	2666 46%	0 0%	0 0%	5 23%	2455 43%	0 0%	309 5%	0 0%	1 0%	0 0%	22 0%	0 0%	360 6%
JUN-2022	29 85%	2710 47%	0 0%	0 0%	5 15%	2454 42%	0 0%	300 5%	0 0%	1 0%	0 0%	22 0%	0 0%	352 6%
JUL-2022	24 69%	2745 47%	0 0%	0 0%	7 20%	2452 42%	3 9%	297 5%	0 0%	1 0%	0 0%	22 0%	1 3%	342 6%
AUG-2022	26 76%	2790 48%	0 0%	0 0%	6 18%	2452 42%	1 3%	294 5%	0 0%	1 0%	1 3%	22 0%	1 3%	340 6%
SEP-2022	19 76%	2820 48%	0 0%	0 0%	6 24%	2433 42%	0 0%	281 5%	0 0%	1 0%	0 0%	21 0%	0 0%	323 6%
OCT-2022	28 80%	2889 49%	0 0%	0 0%	6 17%	2439 41%	1 3%	280 5%	0 0%	1 0%	0 0%	22 0%	0 0%	314 5%
NOV-2022	24 73%	2920 49%	0 0%	0 0%	8 24%	2461 41%	1 3%	276 5%	0 0%	2 0%	0 0%	22 0%	0 0%	309 5%
DEC-2022	16 70%	2974 50%	0 0%	0 0%	5 22%	2463 41%	1 4%	270 4%	0 0%	2 0%	0 0%	20 0%	1 4%	307 5%
JAN-2023	23 82%	3016 50%	0 0%	0 0%	5 18%	2492 41%	0 0%	269 4%	0 0%	2 0%	0 0%	21 0%	0 0%	302 5%
FEB-2023	18 75%	3040 50%	0 0%	0 0%	6 25%	2476 41%	0 0%	255 4%	0 0%	2 0%	0 0%	21 0%	0 0%	288 5%
MAR-2023	25 74%	3084 51%	0 0%	0 0%	5 15%	2482 41%	2 6%	259 4%	0 0%	2 0%	0 0%	20 0%	2 6%	291 5%
APR-2023	22 81%	3084 50%	0 0%	0 0%	4 15%	2498 41%	1 4%	258 4%	0 0%	2 0%	0 0%	18 0%	0 0%	274 4%
MAY-2023	28 67%	3138 51%	1 2%	3 0%	12 29%	2504 41%	1 2%	250 4%	0 0%	2 0%	0 0%	18 0%	0 0%	278 5%
JUN-2023	26 81%	3197 51%	0 0%	5 0%	6 19%	2509 40%	0 0%	248 4%	0 0%	2 0%	0 0%	18 0%	0 0%	267 4%
JUL-2023	25 83%	3218 52%	0 0%	5 0%	5 17%	2499 40%	0 0%	247 4%	0 0%	2 0%	0 0%	18 0%	0 0%	256 4%
AUG-2023	33 79%	3257 52%	0 0%	7 0%	6 14%	2495 40%	1 2%	245 4%	0 0%	2 0%	0 0%	18 0%	2 5%	253 4%
SEP-2023	15 75%	3288 52%	0 0%	8 0%	5 25%	2502 40%	0 0%	238 4%	0 0%	2 0%	0 0%	18 0%	0 0%	249 4%
OCT-2023	22 79%	3297 52%	0 0%	7 0%	6 21%	2524 40%	0 0%	241 4%	0 0%	2 0%	0 0%	18 0%	0 0%	248 4%
NOV-2023	27 82%	3331 53%	0 0%	9 0%	6 18%	2519 40%	0 0%	233 4%	0 0%	2 0%	0 0%	17 0%	0 0%	244 4%
DEC-2023	25 78%	3370 53%	0 0%	13 0%	7 22%	2507 40%	0 0%	228 4%	0 0%	3 0%	0 0%	16 0%	0 0%	237 4%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Fostemsavir not currently on BC-CfE Formulary





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from IV 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2022	985	13.19	773	10.35	4452	59.64	496	6.64	674	9.03	85	1.14
FEB-2022	958	12.97	750	10.15	4409	59.69	522	7.07	668	9.04	79	1.07
MAR-2022	934	12.52	737	9.88	4482	60.10	548	7.35	674	9.04	83	1.11
APR-2022	908	12.24	725	9.77	4473	60.28	565	7.61	670	9.03	79	1.06
MAY-2022	898	12.01	709	9.48	4527	60.55	595	7.96	669	8.95	79	1.06
JUN-2022	873	11.67	705	9.42	4558	60.92	612	8.18	659	8.81	75	1.00
JUL-2022	857	11.43	698	9.31	4578	61.07	632	8.43	655	8.74	76	1.01
AUG-2022	827	11.04	691	9.22	4610	61.52	641	8.55	649	8.66	75	1.00
SEP-2022	799	10.74	691	9.29	4575	61.48	662	8.90	642	8.63	73	0.98
OCT-2022	788	10.55	673	9.01	4619	61.86	678	9.08	637	8.53	72	0.96
NOV-2022	770	10.27	682	9.09	4638	61.83	694	9.25	646	8.61	71	0.95
DEC-2022	774	10.26	663	8.79	4679	62.03	706	9.36	651	8.63	70	0.93
JAN-2023	750	9.89	665	8.77	4728	62.36	718	9.47	649	8.56	72	0.95
FEB-2023	715	9.51	665	8.84	4712	62.65	733	9.75	626	8.32	70	0.93
MAR-2023	699	9.26	653	8.65	4735	62.73	748	9.91	644	8.53	69	0.91
APR-2023	704	9.32	653	8.64	4736	62.70	762	10.09	634	8.39	65	0.86
MAY-2023	706	9.30	644	8.48	4752	62.58	800	10.54	627	8.26	64	0.84
JUN-2023	675	8.88	625	8.22	4788	63.01	819	10.78	627	8.25	65	0.86
JUL-2023	662	8.74	626	8.26	4758	62.80	842	11.11	628	8.29	61	0.81
AUG-2023	643	8.46	621	8.17	4772	62.79	864	11.37	632	8.32	68	0.89
SEP-2023	639	8.40	616	8.09	4793	62.97	879	11.55	618	8.12	66	0.87
OCT-2023	614	8.07	613	8.05	4808	63.16	897	11.78	618	8.12	62	0.81
NOV-2023	611	8.02	601	7.89	4804	63.05	918	12.05	624	8.19	61	0.80
DEC-2023	594	7.80	598	7.85	4814	63.23	937	12.31	615	8.08	56	0.74

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2022	7	1	0	1	1	3	490
FEB-2022	9	0	1	0	1	5	530
MAR-2022	9	4	1	1	1	2	150
APR-2022	1	0	0	0	0	1	820
MAY-2022	13	4	1	1	1	6	490
JUN-2022	15	1	4	1	4	4	400
JUL-2022	13	1	4	3	2	2	225
AUG-2022	17	1	3	3	2	5	330
SEP-2022	15	1	0	3	6	4	405
OCT-2022	16	0	0	1	5	9	520
NOV-2022	17	1	2	2	5	6	445
DEC-2022	8	1	1	2	0	1	320
JAN-2023	10	2	2	2	2	2	285
FEB-2023	11	2	2	3	1	3	253
MAR-2023	21	0	0	4	3	11	530
APR-2023	11	1	3	1	1	4	325
MAY-2023	15	2	1	2	5	2	374
JUN-2023	17	2	4	3	2	6	340
JUL-2023	11	1	2	3	2	3	260
AUG-2023	13	2	1	4	1	2	252
SEP-2023	5	1	1	0	0	3	616
OCT-2023	10	0	1	3	2	3	390
NOV-2023	9	1	1	0	2	4	575
DEC-2023	14	1	0	3	0	9	593

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2022	12277	3734
FEB-2022	12300	3748
MAR-2022	12328	3763
APR-2022	12357	3788
MAY-2022	12348	3777
JUN-2022	12363	3779
JUL-2022	12389	3788
AUG-2022	12410	3800
SEP-2022	12429	3809
OCT-2022	12455	3829
NOV-2022	12463	3819
DEC-2022	12440	3801
JAN-2023	12448	3803
FEB-2023	12436	3788
MAR-2023	12443	3787
APR-2023	12418	3753
MAY-2023	12426	3731
JUN-2023	12399	3693
JUL-2023	12426	3716
AUG-2023	12423	3698
SEP-2023	12410	3685
OCT-2023	12394	3662
NOV-2023	12381	3649
DEC-2023	12403	3656

Definitions:


Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7614
Dec-2023

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Dec-2023

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Dec-2023

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Dec-2023

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Dec-2023

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Dec-2023

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	44	60	28
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	71	101	52	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	451	612	341	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	236	320	170	
Total HA:		802	1093	591

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	5
	20-34	75	76	53
	35-49	189	206	139
	50+	532	805	394
Total HA:		802	1093	591

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	161	222	115
Male	641	871	476

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	591	56	670	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	24	14
	5 years or more	15	9
	<5 years	5	5
	Total HSDA:	44	28
KOOTENAY BOUNDARY	10 years or more	47	33
	5 years or more	13	9
	<5 years	11	10
	Total HSDA:	71	52
OKANAGAN	10 years or more	284	212
	5 years or more	90	65
	<5 years	77	64
	Total HSDA:	451	341
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	145	105
	5 years or more	43	28
	<5 years	48	37
	Total HSDA:	236	170
Total HA:		802	591

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	500	364
5 years or more	161	111
<5 years	141	116
Total HA:	802	591

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	54	95	12	30
KOOTENAY BOUNDARY	76	138	19	42
OKANAGAN	242	1114	54	336
THOMPSON/CARIBOO/SHUSWAP	151	575	36	140
Total:	523	1922	121	548

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	138

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	5
	20-34	44	46	34
	35-49	102	105	70
	50+	273	381	203
	Total HSDA:	426	539	312
FRASER NORTH	20-34	144	145	103
	35-49	357	385	279
	50+	648	1034	488
	Total HSDA:	1149	1564	870
FRASER SOUTH	0-19	7	7	6
	20-34	117	119	88
	35-49	311	339	241
	50+	634	976	499
	Total HSDA:	1069	1441	834
Total HA:		2644	3544	2016

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	14	14	11
	20-34	305	310	225
	35-49	770	829	590
	50+	1555	2391	1190
Total HA:		2644	3544	2016

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	641	823	477
Male	2003	2721	1539

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	2016	53	650	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	284	211
	5 years or more	68	39
	<5 years	74	62
	Total HSDA:	426	312
FRASER NORTH	10 years or more	727	527
	5 years or more	228	178
	<5 years	194	165
	Total HSDA:	1149	870
FRASER SOUTH	10 years or more	653	499
	5 years or more	220	166
	<5 years	196	169
	Total HSDA:	1069	834
Total HA:		2644	2016

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1664	1237
	5 years or more	516	383
	<5 years	464	396
Total HA:		2644	2016

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	151	550	33	64
FRASER NORTH	264	1646	44	223
FRASER SOUTH	227	1838	43	497
Total:	642	4034	120	784

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	212
FRASER NORTH	712
FRASER SOUTH	482
Total:	1406

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		357	531
RICHMOND	20-34	31	32	20
	35-49	60	61	51
	50+	125	182	103
	Total HSDA:	216	275	174
VANCOUVER	0-19	10	10	8
	20-34	450	467	306
	35-49	1226	1366	855
	50+	2997	5397	2131
	Total HSDA:	4683	7240	3300
Total HA:		5256	8046	3743

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	11	11	9
	20-34	508	526	341
	35-49	1360	1508	960
	50+	3377	6001	2433
Total HA:		5256	8046	3743

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	602	981	445
Male	4652	7063	3298
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3743	56	660	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	250	190
	5 years or more	51	41
	<5 years	56	38
	Total HSDA:	357	269
RICHMOND	10 years or more	127	99
	5 years or more	34	26
	<5 years	55	49
	Total HSDA:	216	174
VANCOUVER	10 years or more	*	2268
	5 years or more	*	533
	<5 years	*	499
	Never on ART	*	0
	Total HSDA:	4683	3300
Total HA:	5256	3743	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	*	2557
5 years or more	*	600
<5 years	*	586
Never on ART	*	0
Total HA:	5256	3743

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	189	417	34	49
RICHMOND	47	322	8	99
VANCOUVER	700	11847	226	5479
Total:	936	12586	268	5627

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	63

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		357	525
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		133	186
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		828	1186
Total HA:		1318	1897	1000

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	6
	20-34	110	119	71
	35-49	308	346	230
	50+	894	1426	693
Total HA:		1318	1897	1000

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	221	323	167
Male	1097	1574	833

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1000	56	610	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	230	186
	5 years or more	67	46
	<5 years	60	51
	Total HSDA:	357	283
NORTH VANCOUVER ISLAND	10 years or more	97	78
	5 years or more	25	16
	<5 years	11	10
	Total HSDA:	133	104
SOUTH VANCOUVER ISLAND	10 years or more	513	369
	5 years or more	157	115
	<5 years	158	129
	Total HSDA:	828	613
Total HA:		1318	1000

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	840	633
	5 years or more	249	177
	<5 years	229	190
Total HA:		1318	1000

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	206	937	68	174
NORTH VANCOUVER ISLAND	161	287	36	68
SOUTH VANCOUVER ISLAND	230	1986	40	590
Total:	597	3210	144	832

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	101
NORTH VANCOUVER ISLAND	47
SOUTH VANCOUVER ISLAND	129
Total:	277

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	8	8	*
	35-49	18	21	*
	50+	30	39	*
	Total HSDA:	56	68	29
NORTH WEST	20-34	*	5	*
	35-49	*	38	*
	50+	*	80	*
	Total HSDA:	75	123	60
NORTHERN INTERIOR	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	204	304	151
Total HA:		335	495	240

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		335	495	240

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	116	177	79
Male	219	318	161

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	240	53	560	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	32	*
	5 years or more	6	*
	<5 years	18	*
	Total HSDA:	56	29
NORTH WEST	10 years or more	53	41
	5 years or more	10	9
	<5 years	12	10
	Total HSDA:	75	60
NORTHERN INTERIOR	10 years or more	117	88
	5 years or more	50	35
	<5 years	37	28
	Total HSDA:	204	151
Total HA:		335	240

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	202	142
	5 years or more	66	46
	<5 years	67	52
Total HA:		335	240

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	39	51	6	8
NORTH WEST	88	168	13	30
NORTHERN INTERIOR	125	508	24	195
Total:	252	727	43	233

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	7
NORTH WEST	27
NORTHERN INTERIOR	17
Total:	51

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	9	*
	OKANAGAN	*	52	*
	THOMPSON/CARIBOO/SHUSWAP	*	53	*
	Total HA:	68	124	46
FRASER	FRASER EAST	37	53	32
	FRASER NORTH	51	94	38
	FRASER SOUTH	81	120	58
	Total HA:	169	267	128
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	27	54	24
	RICHMOND	6	11	5
	VANCOUVER	447	914	359
	Total HA:	480	979	388
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	48	83	39
	NORTH VANCOUVER ISLAND	16	30	12
	SOUTH VANCOUVER ISLAND	48	96	36
	Total HA:	112	209	87
NORTHERN	NORTH EAST	12	16	5
	NORTH WEST	33	69	26
	NORTHERN INTERIOR	73	121	59
	Total HA:	118	206	90
Total:		947	1785	739

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	604	1147	468
Female	343	638	271

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	739	54	530	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

Cabenuva: the ViiV Healthcare trade name for an injectable formulation containing CABOTEGRAVIR and RILPIVIRINE.

Cabotegravir: an INTEGRASE INHIBITOR.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.





Monthly Report

Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fostemsavir: an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.





Monthly Report

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.





Monthly Report

Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

